FDA
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
-
-
-
-
-
-
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
-
-
-
-
-
-
FDA approves Arrowhead's REDEMPLO for rare triglyceride disorder
-
-
-
-
-
-
-
Sanofi acquires rights to plozasiran drug candidate in Greater China
-
-
-
-
-
-
-
B.Riley Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Inc. (ARWR) Submits New Drug Application to U.S. FDA for Plozasiran
-
325,138 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

